Skip to content

Comparative Imaging Assessment of Valvular Heart Disease

Assessment of Left Ventricular Volumes and Strain and Assessment of Valvular Lesions Using Two- and Three-dimensional Echocardiography and Cardiac MRI, a Correlation Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04126018
Enrollment
200
Registered
2019-10-14
Start date
2019-08-23
Completion date
2027-12-31
Last updated
2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Regurgitation, Aortic Stenosis, Valve Heart Disease

Brief summary

The purpose of the study is to compare the various 2D and 3D methods of valvular heart disease quantification (Doppler, PISA, VCA, volumetric method) and strain with cardiac magnetic resonance (CMR) measurements of left and right ventricular systolic function strain and myocardial fibrosis assessment.

Detailed description

The objective of this study is to compare the accuracy of 3D TTE to 2D TTE in assessing the severity of valvular heart disease in patients with aortic stenosis, aortic regurgitation, and mitral valve regurgitation by comparing this to the reference standard of cardiac magnetic resonance (CMR) in subjects with different etiologies and mechanisms of valvular lesions and to the integrative method of valvular lesion grading as recommended by inter-societal guidelines. Another objective is to assess prevalence of focal and diffuse myocardial fibrosis as assessed by CMR in patients with aortic stenosis, aortic regurgitation and mitral regurgitation. In addition, the investigators aim to determine whether severity of myocardial fibrosis predicts onset of symptoms, referral for valve surgery and adverse ventricular remodeling. The investigators also aim to look at patients who will be undergoing CRT implant to predict their response to therapy. At baseline, the Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire will be completed. A 6-12 month follow-up is required and will include an abbreviated non-contrast research cardiac MRI and subject questionnaires. Other follow-up will include using electronic medical records and the Social Security Death Index database for outcomes such as death, hospitalization for heart failure, mitral or aortic valve interventions and cardiovascular death. Select patients will be asked to undergo a supine bicycle exercise stress MRI at enrollment. Approximately 40 subjects will be included in this substudy. Additional exclusion criteria for this substudy: * Unable to pedal a supine bicycle * Require supplemental oxygen During the exercise stress MRI, patients will be asked to cycle on a supine bike that will be mounted on the MRI platform. During this test, a caregiver will be present. An electrocardiogram (ECG) will be used to obtain tracings of cardiac activity. Respirations, blood pressure, and heart rate are also monitored during exercise. The test is continued until peak exercise level or target heart rate is achieved. As soon as the exercise portion is complete, MRI images will be acquired. When the test is complete, patients will be monitored until ECG, heart rate, and breathing have returned to baseline. Patients will be assessed for symptoms such as chest pain, dyspnea, leg pain, dizziness, or fatigue and may be given medications or instructed to stop the test early as necessary.

Interventions

DIAGNOSTIC_TESTEchocardiography

Doppler, PISA, VCA, volumetric method as performed during echocardiography

DIAGNOSTIC_TESTMRI with strain measurement

CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis

Sponsors

The Cleveland Clinic
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-90 years of age * Suspected moderate or severe MR,AR or AS on the basis of prior known clinical history or clinical exam. * Suspected CRT non-responder with an implanted MRI compatible CRT device and reduced ejection fraction

Exclusion criteria

* Acute traumatic cardiac injury * Aortic dissection or aortic root rupture * Congenital heart diseases such as patent ductus arteriosus, coarctation of aorta, ASD and VSD * Presence of A-V fistula or intracardiac shunts * Any contraindications to CMR * Moderate or severe dysfunction in multiple valves * Patients with significant claustrophobia

Design outcomes

Primary

MeasureTime frameDescription
Development of class I or IIa indication for valve surgery6 MonthsThe recommended indications for surgery include: development of symptoms, LV dysfunction (LV end-systolic diameter ≥45 mm or LV ejection fraction ≤60%), and new onset of atrial fibrillation or pulmonary hypertension (systolic pulmonary artery pressure \>50 mm Hg at rest).
Change in MRI Quantified LVEDVi6 months10% Change from Baseline - units of measure cc/m2
Change in MRI Quantified LVESVi6 months15% Change from Baseline - units of measure cc/m2
Change in MRI Quantified LV Strain6 months5% Change from Baseline
Change in MRI LVEF6 Months5% Change from Baseline
Change in Kansas City Cardiomyopathy Questionnaire Answers6 MonthsChange in quality of life related to heart failure symptoms.
Change in Physical Activity Questionnaire Answers6 MonthsChange in physical activity level due to heart failure symptoms.
All-cause mortality6 Monthsnumber of patients expired

Secondary

MeasureTime frameDescription
Accuracy of echocardiography as compared with MRI6 MonthsComparison of MRI measurements based on standard of care echocardiography.

Countries

United States

Contacts

Primary ContactDeborah Kwon, M. D.
kwond@ccf.org216-444-8526

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026